Drug Profile
ACE 527
Alternative Names: ACAM-2010; ACE-537; ACE527; ETEC vaccine - Cambridge Biostability; ETEC vaccine - Zymenex; HolaVax; HolaVax-ETEC vaccineLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Acambis
- Developer ACE BioSciences; TD Vaccines A/S
- Class Escherichia coli vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Escherichia coli infections
Most Recent Events
- 29 Mar 2010 Phase-II clinical trials in Escherichia coli infections in USA (PO)
- 09 Nov 2009 ACE BioSciences has been acquired by Zymenex A/S
- 19 May 2009 ACE 527 is in active development for Escherichia coli infections in USA